JIANGXI FUSHINE PHARMACEUTICAL CO., LTD.

Jiangxi Fushine Pharmaceutical Co., Ltd.

300497

CNE1000024Z7

Pharmaceuticals

End-of-day quote Shenzhen S.E. Other stock markets 06:00:00 2024-04-25 pm EDT			5-day change	1st Jan Change
9.5 ^CNY	+5.32%		+20.56%	+1.50%

Feb. 19	Fushine Pharma's Unit Gets Nod for Tazobactam Sodium	MT
2023	Jiangxi Fushine Pharmaceutical Co., Ltd. announced that it expects to receive CNY 300 million in funding	CI

Jiangxi Fushine Pharmaceutical Co., Ltd. authorizes a Buyback Plan.

August 03, 2021

The Board of Directors of Jiangxi Fushine Pharmaceutical Co., Ltd. has authorized a buyback plan on August 4, 2021.

Latest news about Jiangxi Fushine Pharmaceutical Co., Ltd.

Fushine Pharma's Unit Gets Nod for Tazobactam Sodium	Feb. 18	MT
Jiangxi Fushine Pharmaceutical Co., Ltd. announced that it expects to receive CNY 300 million in funding	Dec. 03	CI
Fushine Pharmaceutical's Unit Gets Nod to Market Antidepressant	Nov. 21	MT
Jiangxi Fushine Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-24	CI
Jiangxi Fuxiang Pharma to Invest 32.5 Million Yuan in New Biotechnology Unit	23-10-05	MT
Jiangxi Fushine Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-30	CI
Fuxiang Pharma's Profit to Rise in H1	23-07-12	MT
Fuxiang Pharma’s Vice Chairman, Deputy General Manager to Boost Shareholding	23-06-19	MT
Fushine Pharma Earmarks 386 Million Yuan to Build New Chemical Factory	23-05-23	MT
Jiangxi Fushine Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-25	CI
Jiangxi Fushine Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	23-04-25	CI
Jiangxi Fushine Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022	22-10-26	CI
Jiangxi Fushine Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022	22-08-26	CI
Tranche Update on Jiangxi Fushine Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on August 4, 2021.	22-07-03	CI
Jiangxi Fushine Pharmaceutical Co., Ltd.'s Equity Buyback announced on August 4, 2021, has expired with 11,355,900 shares, representing 2.09% for CNY 174.83 million.	22-06-29	CI
LinkChem Co., Ltd. announced that it has received CNY 117 million in funding from Jiangxi Fushine Pharmaceutical Co., Ltd.	22-06-20	CI
Jiangxi Fushine Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-04-28	CI
Jiangxi Fushine Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021	22-04-28	CI
LinkChem Co., Ltd. announced that it expects to receive CNY 117 million in funding from Jiangxi Fushine Pharmaceutical Co., Ltd.	22-04-17	CI
Tranche Update on Jiangxi Fushine Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on August 4, 2021.	22-04-01	CI
Tranche Update on Jiangxi Fushine Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on August 4, 2021.	22-01-05	CI
Jiangxi Fushine Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2021	21-10-26	CI
Tranche Update on Jiangxi Fushine Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on August 4, 2021.	21-10-11	CI
Jiangxi Fushine Pharmaceutical Co., Ltd.(XSEC:300497) added to S&P Global BMI Index	21-09-20	CI
Jiangxi Fushine Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2021	21-08-11	CI

Chart Jiangxi Fushine Pharmaceutical Co., Ltd.

Duration

Period

Chart Jiangxi Fushine Pharmaceutical Co., Ltd.

More charts

Jiangxi Fushine Pharmaceutical Co., Ltd. is principally engaged in research and development, manufacturing and sales of bulk drugs, pharmaceutical intermediates and related products. The Company's main products include sulbactam series enzyme inhibitor bulk drugs, pharmaceutical intermediates and related products, tazobactam series enzyme inhibitor bulk drugs, pharmaceutical intermediates and related products, as well as intermediates of carbapenems bulk drugs. The Company distributes its products within domestic markets and to overseas markets, including European Union (EU) and other countries and regions in Asia.

Sector

Pharmaceuticals

Calendar

2024-04-28 - Q1 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
JIANGXI FUSHINE PHARMACEUTICAL CO., LTD.	+1.50%	671M
ELI LILLY AND COMPANY	+25.83%	653B
NOVO NORDISK A/S	+27.00%	556B
JOHNSON & JOHNSON	-6.76%	354B
MERCK & CO., INC.	+20.34%	331B
ABBVIE INC.	+3.00%	296B
ASTRAZENECA PLC	+13.09%	233B
NOVARTIS AG	+5.46%	201B
ROCHE HOLDING AG	-9.61%	193B
AMGEN INC.	-6.26%	144B

Other Pharmaceuticals